Overview

First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy

Status:
Completed

Trial end date:
2017-10-19

Target enrollment:

Participant gender:

Summary

The purpose of this study was to evaluate the safety and tolerability of VX-984 (M9831) administered alone and in combination with pegylated liposomal doxorubicin (PLD), and to determine the maximum tolerated dose (MTD) and preliminary evidence of efficacy of VX-984 in combination with PLD in participants with advanced solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

EMD Serono Research & Development Institute, Inc.
Vertex Pharmaceuticals Incorporated

Collaborator:

Merck KGaA, Darmstadt, Germany

Treatments:

Doxorubicin
Liposomal doxorubicin